Chemical Peel Concentration Science: AHA 10–30% Neutralization & Skin Response Protocol

Overview #

Chemical peel formulations sit at the intersection of cosmetic efficacy and regulatory risk — get the concentration or pH wrong, and you are not just dealing with a failed product, you are dealing with a rejected registration or a market recall. Our acid exfoliation technology team works daily with AHA concentrations from 5% up to 30%, and the single most common problem we see from incoming brand briefs is treating EU, US, and China as interchangeable markets. They are not. Each jurisdiction sets its own permitted limits, labeling triggers, and safety assessment requirements, and the documentation package you need for NMPA looks nothing like what the EU Responsible Person needs. This guide walks through exactly what we prepare for each market, the numeric thresholds that govern our formulation decisions, and the compliance timeline brand partners should plan around.

AHA Concentration Limits and pH Thresholds by Regulatory Market #

The three major markets — EU, US, and China — each approach AHA regulation from a different philosophical starting point, and that directly shapes how we formulate the same active at different concentrations for different destinations.

Under the EU Cosmetics Regulation 1223/2009, glycolic acid and other AHAs used as exfoliants in rinse-off and leave-on products are subject to concentration caps and mandatory labeling. For leave-on products, the permitted AHA concentration is up to 10% at a minimum pH of 3.5. Rinse-off products may go up to 10% as well, but the critical control point is the pH floor — formulations must not drop below pH 3.5 in the finished product. Any product making an exfoliation claim must carry the warning: “Contains AHA. May increase skin’s sensitivity to the sun. Use sunscreen.” The SCCS Scientific Opinion on AHAs, last updated in 2015, underpins these limits and remains the reference document our EU safety assessors cite in every Product Information File (PIF).

In the US, the FDA Cosmetics Guidelines do not set a hard statutory cap on AHA concentration for OTC cosmetics, but the Cosmetic Ingredient Review (CIR) and the PCPC have established a voluntary industry standard: AHA concentrations up to 10% at pH ≥ 3.5 for consumer products, and up to 30% at pH ≥ 3.0 for professional-use products. When brand partners brief us on professional peel kits for the US market, the first question we ask is: “Is this sold direct-to-consumer or exclusively through licensed estheticians?” That single answer determines whether we formulate at 15% or 30% glycolic acid, and whether the product needs a professional-use-only label.

China’s NMPA Cosmetic Regulation is the most prescriptive of the three. Under the 2021 Cosmetic Supervision and Administration Regulation (CSAR) and its associated technical guidelines, AHAs are classified as functional ingredients requiring registration — not just notification — when used above 6% in leave-on products. Glycolic acid at concentrations above 6% triggers the “special cosmetics” pathway, which requires clinical safety data, a full dossier submission, and NMPA review before market entry. The review timeline alone runs 6–12 months for new formulations.

The table below summarizes the key regulatory parameters across all three markets:

Neutralization Protocol and Skin Response: Formulation Science Behind the Numbers #

Neutralization is where most peel formulations either succeed or fail on the production line. When we manufacture a 20% glycolic acid peel at pH 3.2 for a professional brand, we are not simply mixing acid and water — we are managing a buffered system where the free acid concentration, the pH, and the neutralization agent all interact to determine both efficacy and safety margin.

In our formulation lab, we stabilize glycolic acid peels in the pH 3.0–3.5 range using a sodium hydroxide partial neutralization approach, targeting a free acid content of 12–15% even when total glycolic acid is 20%. The distinction between total AHA concentration and free acid concentration matters enormously for both efficacy and regulatory compliance. A 20% glycolic acid solution at pH 3.5 has approximately 60% of the acid in the free (protonated) form — that is the biologically active fraction driving keratinocyte desquamation.

For neutralization on the skin, we formulate companion neutralizing solutions at pH 7.0–7.5 using 8–10% sodium bicarbonate in water. On our production line, we see a failure mode when brands try to use a single-step water rinse instead of an active neutralizer — the pH at the skin surface drops back only to approximately pH 5.5 after rinsing, which is insufficient to fully arrest the peel reaction in a 20–30% formulation.

A 2019 split-face randomized controlled trial (n=48, 12 weeks, 6 biweekly peel sessions) comparing 20% glycolic acid at pH 3.2 versus 30% glycolic acid at pH 3.5 showed a 34% reduction in melanin index scores in the 20% group and a 41% reduction in the 30% group, with no statistically significant difference in adverse event rates between the two concentrations when a standardized sodium bicarbonate neutralization protocol was applied. This data supports our recommendation to brand partners that concentration alone is not the primary efficacy driver — pH control and neutralization protocol are equally determinative.

Our barrier repair and sensitive skin formulation team is often brought in when a brand wants to add post-peel recovery actives — ceramides at 1–3%, panthenol at 2–5%, or niacinamide at 4% — to the same product line. The compatibility work here is non-trivial: niacinamide at pH below 4.0 undergoes hydrolysis to nicotinic acid at a measurable rate, so we always position niacinamide in the post-peel recovery step, not in the peel itself.

For accelerated stability testing, we run peel formulations at 40°C / 75% RH for 8 weeks as a proxy for 24-month real-time shelf life. Glycolic acid concentration drift in a well-buffered system should not exceed 2% relative over that period. If we see more than 3% drift at the 4-week check, we revisit the buffer system before proceeding to real-time stability.

Regulatory Documentation Package by Market #

The documentation we prepare for brand partners varies substantially by destination market, and understanding what is required before you brief us saves 4–6 weeks of back-and-forth.

For the EU market, every cosmetic product requires a Product Information File (PIF) maintained by a Responsible Person established in the EU or UK. The PIF must include a Cosmetic Product Safety Report (CPSR) signed by a qualified safety assessor, the full formulation with INCI names and concentrations, stability data, microbiological challenge test results, and the product label in the language of each member state where it is sold. For AHA products above 10% — which are not permitted for consumer sale in the EU — we do not submit a CPNP notification; instead, we advise the brand that the formulation must be reformulated to ≤10% for EU consumer channels. Notification via the EU Cosmetics Regulation 1223/2009 CPNP portal typically takes 4–8 weeks from completed dossier to market-ready status.

For the US market, there is no pre-market registration requirement for cosmetics under current FDA authority. However, the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) introduced mandatory facility registration and product listing requirements, with the FDA’s compliance deadline having passed in 2024. We prepare a complete ingredient disclosure list, safety substantiation file, and facility registration documentation as part of our standard US export package. Brands selling professional peels above 10% AHA must ensure their distribution channel is restricted to licensed professionals — this is a liability and labeling issue, not a statutory concentration cap, but the FDA Cosmetics Guidelines make clear that products causing physiological changes beyond the skin surface may be regulated as drugs.

For China, the documentation burden is the heaviest. Products containing AHAs above 6% require a special cosmetics registration dossier that includes: full formulation disclosure, raw material safety data, manufacturing process description, quality control standards, finished product testing (including heavy metals, microbiological limits, and pH), and a clinical safety evaluation conducted at a NMPA-recognized testing institution. We work with three NMPA-recognized testing partners and can coordinate the clinical safety evaluation as part of our ODM service. The NMPA Cosmetic Regulation dossier review for special cosmetics currently runs 6–12 months, and we advise brands to initiate this process in parallel with product development, not after it.

For brands targeting all three markets simultaneously, we prepare a master dossier structured to satisfy the most demanding requirements (China/EU) while generating the subset documents needed for the US filing. This approach typically reduces total documentation preparation time by 30–40% compared to preparing three separate dossiers sequentially.

The ICH Stability Guidelines Q1A(R2) framework informs our stability study design even for cosmetic products, because brands selling into regulated markets increasingly face retailer and insurer requests for ICH-aligned stability data. We run real-time stability at 25°C / 60% RH and accelerated at 40°C / 75% RH as standard, with 24-month real-time studies initiated at the same time as accelerated testing.

Formulation Notes for Brand Partners #

When you brief us on a chemical peel project, the first information we need is your target market — not your preferred concentration. The market determines the concentration ceiling, the pH floor, the labeling requirements, and the registration pathway, and all of those constrain the formulation before we touch a single ingredient. We also need to know your intended distribution channel (consumer retail, professional salon, e-commerce) and your target consumer skin type, because a 10% glycolic acid peel for sensitive skin in the EU requires a very different buffer system and post-peel recovery strategy than a 20% professional peel for the US market.

The most common brief mistake we see is brands specifying a concentration — “we want a 20% glycolic peel” — without specifying the market. We have had to rebrief brands who had already designed packaging for a 20% leave-on product intended for EU retail, which is not permitted under current EU limits. We guide partners through a market-first formulation decision tree before any lab work begins.

Timeline: lab samples in 2–3 weeks from confirmed brief, accelerated stability over 4–8 weeks, 24-month real-time stability initiated concurrently. For China special cosmetics registration, add 6–12 months for NMPA review — plan your launch timeline accordingly.

Frequently Asked Questions #

Q1: What is the maximum glycolic acid concentration we can use in a consumer leave-on product sold across EU, US, and China simultaneously?
A: The binding constraint is China’s NMPA limit of 6% for leave-on products without special cosmetics registration. If you want a single SKU compliant in all three markets without triggering China’s special cosmetics pathway, we formulate at ≤6% glycolic acid at pH ≥ 3.5. Above 6%, the product requires separate China registration and a 6–12 month NMPA review timeline before it can be sold in that market.

Q2: Does the EU require a specific safety assessment for AHA products, and who can sign it?
A: Yes — under the EU Cosmetics Regulation 1223/2009, every product sold in the EU requires a Cosmetic Product Safety Report (CPSR) signed by a qualified safety assessor with a minimum of a relevant university degree in pharmacy, toxicology, medicine, or a related discipline. For AHA products, the CPSR must specifically address the sun-sensitivity risk and confirm that the formulation meets the ≤10% concentration and pH ≥ 3.5 requirements. We coordinate with our EU safety assessor network to prepare this document as part of the export package.

Q3: How do you ensure glycolic acid concentration stays stable over the product’s shelf life?
A: In our accelerated stability protocol at 40°C / 75% RH over 8 weeks, a well-buffered glycolic acid formulation should show no more than 2% relative concentration drift. We use a citrate-phosphate buffer system to maintain pH within ±0.2 units of the target throughout the stability period. If we see drift exceeding 3% at the 4-week check, we reformulate the buffer before proceeding — this is a non-negotiable quality gate in our production process.

Q4: What is the MOQ for a custom AHA peel formulation, and how long does the sample process take?
A: Our standard MOQ for a custom chemical peel formulation is 500 kg per SKU for production batches. For the development phase, we produce lab samples of 100–200 g within 2–3 weeks of receiving a confirmed brief with market, concentration target, and texture preference. Pilot batches of 20–50 kg are available for stability and consumer testing before committing to full production MOQ.

Q5: What is the most common formulation failure mode you see with high-concentration AHA peels on the production line?
A: The most frequent failure is pH drift during manufacturing when the neutralization step is not tightly controlled. On our production line, we see finished product pH landing 0.3–0.5 units below target when the sodium hydroxide titration rate is too fast, which pushes free acid content above the intended level and can take a 20% glycolic formulation outside its validated safety window. We control this with in-process pH checks at every 500 kg batch increment and a hold-and-recheck protocol if pH deviates more than 0.2 units from the target range.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.